Enovis Corp (ENOV)

Enovis Corporation is a healthcare company focused on medical technology for musculoskeletal care in the United States and international markets. Its operations are organized into two segments. Prevention and Recovery includes orthopedic bracing, therapy products, bone growth stimulators, compression and vascular therapy systems, electrical stimulators for pain management, and related rehabilitation products used by healthcare professionals treating musculoskeletal conditions. Reconstructive develops and markets surgical solutions designed to support mobility and patient outcomes, including implants, instrumentation, and enabling technologies for joint replacement, limb reconstruction, and foot and ankle procedures. The company also supplies products used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Enovis distributes its products through independent distributors, direct sales representatives, and patient channels. Formerly known as Colfax Corporation, the company was founded in 1995 and is headquartered in Wilmington, Delaware.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NYSE-ENOV
$27.06
28.4% Upside
Undervalued
$36.08
71.2% Upside
Bargain
Good
0.0%
November 5, 2026
0.8x
0.5x
1.216 B
2.574 B
52.9%
91.5%
1.0
-5.8%
Valuation • Fair Value

Enovis Corp (NYSE-ENOV) Fair Value by Valuation Model

Review the available estimates for Enovis Corp (NYSE-ENOV), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$27.06

Estimated upside of 28.4% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$26.96

Discounted cash flow valuation reference.

Comps Fair Value

$27.17

Comparable-company valuation reference.

Analyst Price Target

$36.08

Analysts imply upside of 71.2%.

How to read these valuation models

Use the 5 available valuation references for Enovis Corp (NYSE-ENOV) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Enovis Corp (NYSE-ENOV)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

2.297 B

Current operating scale indicator.

Revenue Forecast

2.339 B

Forward revenue estimate.

EBITDA

379.8 M

Current operating profitability reference.

EBITDA Forecast

427.6 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Enovis Corp (NYSE-ENOV) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Enovis Corp (NYSE-ENOV)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-4.39

No elevated caution signal from this screen.

Altman Z-Score

1.0

Lower score that deserves closer risk review.

FCF / Net Income

-5.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Enovis Corp (NYSE-ENOV). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Enovis Corp (NYSE-ENOV)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 5, 2026

Days to Earnings

12

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Enovis Corp (NYSE-ENOV), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Enovis Corp (NYSE-ENOV) Stock Forecast & Technical Outlook

Review Enovis Corp (NYSE-ENOV) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Enovis Corp (NYSE-ENOV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Enovis Corp (NYSE-ENOV) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Enovis Corp (NYSE-ENOV) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Enovis Corp (NYSE-ENOV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Enovis Corp (NYSE-ENOV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Enovis Corp (NYSE-ENOV)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Enovis Corp (NYSE-ENOV) has a Strong Buy consensus, with 10 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 10
Hold 1
Sell 0
FAQ • Fast Investor Answers

Enovis Corp (NYSE-ENOV) Stock FAQ

Data-supported answers about Enovis Corp (NYSE-ENOV), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$27.06
Estimated upside 28.4%
Valuation Rating
Undervalued
Estimated upside of 28.4%
Analyst Target
$36.08
Implied upside 71.2%
Financial Health
Good
Current financial-health read

The current fair value estimate for Enovis Corp (NYSE-ENOV) is $27.06. This implies an estimated upside of 28.4% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 28.4% versus the current market price.

The available analyst price target for Enovis Corp (NYSE-ENOV) is $36.08. The analyst target implies estimated upside of 71.2%.

The current financial health read for Enovis Corp (NYSE-ENOV) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Enovis Corp (NYSE-ENOV) is November 5, 2026.

The latest available data indicates no current dividend yield for Enovis Corp (NYSE-ENOV).

The current market capitalization listed for Enovis Corp is 1.216 B.

The current enterprise value listed for Enovis Corp is 2.574 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Enovis Corp is NYSE-ENOV, and the stock is listed on NYSE.

Enovis Corp (NYSE-ENOV) is listed on NYSE.

The current debt-to-total-capital ratio listed for Enovis Corp is 52.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Enovis Corp is 91.5%. Free float helps investors understand how much of the share base is available for public trading.